Results 81 to 90 of about 5,730 (206)

Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents [PDF]

, 2016
Association between HCV infection and diabetes has been widely postulated. Little is known about the impact of direct acting antiviral agents (DAAs) on glycemic control. Aim of our study was to evaluate the glycemic control modifications in a case series
D'Ettorre, G., LICHTNER, Miriam, MAROCCO, RAFFAELLA, MASTROIANNI, Claudio Maria, MEZZAROMA, Ivano, Passavanti, G., pavone, paolo, TIEGHI, TIZIANA, VITTOZZI, PIETRO, VULLO, Vincenzo   +9 more
core   +1 more source

Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population

Clinical and Translational Science, Volume 17, Issue 10, October 2024.
Abstract Next‐generation sequencing (NGS) has transformed pharmacogenomics (PGx), enabling thorough profiling of pharmacogenes using computational methods and advancing personalized medicine. The Thai Pharmacogenomic Database‐2 (TPGxD‐2) analyzed 948 whole genome sequences, primarily from the Electricity Generating Authority of Thailand (EGAT) cohort ...
Shobana John, Sommon Klumsathian, Paravee Own‐eium, Angkana Charoenyingwattana, Jakris Eu‐ahsunthornwattana, Thanyachai Sura, Donniphat Dejsuphong, Piyamitr Sritara, Prin Vathesatogkit, Nartthawee Thongchompoo, Wiphaporn Thabthimthong, Nuttinee Teerakulkittipong, Wasun Chantratita, Chonlaphat Sukasem   +13 more
wiley   +1 more source

Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity

European Journal of Immunology, Volume 54, Issue 8, August 2024.
In patients with hepatitis C cirrhosis who are treated with 2G DAA, predicted weak NK‐cell‐mediated immunity may predispose to HCC development more than predicted intermediate or strong NK‐cell‐mediated immunity. Background and aims Second‐generation direct‐acting antivirals (2G DAA) to cure HCV have led to dramatic clinical improvements.
James C. Ryan, Christina Haight, Erene C. Niemi, Joshua D. Grab, Jennifer L. Dodge, Lewis L. Lanier, Alexander Monto   +6 more
wiley   +1 more source

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Advances in Virology, 2020
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities.
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany, Sherief Abd-Elsalam   +9 more
doaj   +1 more source

Reassessment of genotype 1 hepatitis c virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment [PDF]

, 2014
The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing.
Di Lello, Federico Alejandro, Guelfo, Javier R., Macias, Juan, Mancebo, María, Merchante, Nicolás, Mira José Antonio, Neukam, Karin, Nuñez Torres, Rocío, Pineda, Juan A., Real. Luis M.   +9 more
core   +1 more source

Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Annals of Hepatology, 2018
Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available ...
Mitsuyoshi Suzuki, Kei Minowa, Hitoshi Tajiri   +2 more
doaj   +1 more source

A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]

, 2015
Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core   +1 more source

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Liver International, Volume 44, Issue 5, Page 1075-1092, May 2024.
Abstract Background and Aims The beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached.
Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto   +6 more
wiley   +1 more source

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice

Журнал инфектологии, 2016
The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical ...
N. P. Blokhina, E. A. Nurmuhametova, M. G. Rusanova, I. V. Gagarina, E. S. Mar’jamova, N. A. Kuznetsova, T. V. Mar’janovskaja, T. V. Lopatina, O. V. Kuzina, I. N. Alekseeva, E. N. Shurenkova, A. V. Devjatkin, Yu. N. Linkova, M. A. Morozova   +13 more
doaj  

Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Genetics and Molecular Biology
Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued.
Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri   +7 more
doaj   +1 more source